BIBCL -- India Stock  

INR 6.50  0.80  10.96%

The firm owns Beta (Systematic Risk) of 0.752 which signifies that as returns on market increase, BHARAT IMMUNOLOGICALS returns are expected to increase less than the market. However during bear market, the loss on holding BHARAT IMMUNOLOGICALS will be expected to be smaller as well. Even though it is essential to pay attention to BHARAT IMMUNOLOGICALS existing price patterns, it is always good to be careful when utilizing equity price patterns. Macroaxis approach to foreseeing future performance of any stock is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. BHARAT IMMUNOLOGICALS exposes twenty-one different technical indicators which can help you to evaluate its performance. BHARAT IMMUNOLOGICALS has expected return of -0.1312%. Please be advised to confirm BHARAT IMMUNOLOGICALS BIOLOG Jensen Alpha, Semi Variance and the relationship between Standard Deviation and Value At Risk to decide if BHARAT IMMUNOLOGICALS past performance will be repeated at some future date.

Risk-Adjusted Performance

Over the last 30 days BHARAT IMMUNOLOGICALS BIOLOG has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.
Fifty Two Week Low5.75
Fifty Two Week High20.20
Horizon     30 Days    Login   to change

BHARAT IMMUNOLOGICALS Relative Risk vs. Return Landscape

If you would invest  701.00  in BHARAT IMMUNOLOGICALS BIOLOG on July 20, 2019 and sell it today you would lose (51.00)  from holding BHARAT IMMUNOLOGICALS BIOLOG or give up 7.28% of portfolio value over 30 days. BHARAT IMMUNOLOGICALS BIOLOG is generating negative expected returns and assumes 4.3387% volatility on return distribution over the 30 days horizon. Simply put, 38% of equities are less volatile than BHARAT IMMUNOLOGICALS and 99% of equity instruments are likely to generate higher returns than the company over the next 30 trading days.
 Daily Expected Return (%) 
      Risk (%) 
Assuming 30 trading days horizon, BHARAT IMMUNOLOGICALS is expected to under-perform the market. In addition to that, the company is 4.77 times more volatile than its market benchmark. It trades about -0.03 of its total potential returns per unit of risk. The DOW is currently generating roughly -0.08 per unit of volatility.


Sharpe Ratio = -0.0302
Good Returns
Average Returns
Small Returns
Negative ReturnsBIBCL

BHARAT IMMUNOLOGICALS Relative Performance Indicators

Estimated Market Risk
  actual daily
 38 %
of total potential
Expected Return
  actual daily
 0 %
of total potential
Risk-Adjusted Return
  actual daily
 0 %
of total potential
Based on monthly moving average BHARAT IMMUNOLOGICALS is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BHARAT IMMUNOLOGICALS by adding it to a well-diversified portfolio.


Equity Alerts and Improvement Suggestions

BHARAT IMMUNOLOGICALS is not yet fully synchronised with the market data
BHARAT IMMUNOLOGICALS generates negative expected return over the last 30 days
BHARAT IMMUNOLOGICALS has high historical volatility and very poor performance
BHARAT IMMUNOLOGICALS has high likelihood to experience some financial distress in the next 2 years
The company reported revenue of 836.45M. Net Loss for the year was (55.57M) with profit before overhead, payroll, taxes, and interest of 103.65M.
Check also Trending Equities. Please also try Financial Widgets module to easily integrated macroaxis content with over 30 different plug-and-play financial widgets.